速効型インスリンの世界市場、市場規模とシェアの分析 - 成長動向と予測（2025年～2033年）

速効型インスリン市場の動向とサマリー

世界の速効型インスリンの市場規模は、2024年に77億1,000万米ドルであり、2033年までに117億7,000万米ドルに急成長すると予測され、2025年～2033年にCAGRで4.81%の成長が見込まれます。

速効型インスリン市場の成長促進要因

世界の糖尿病有病率の増加

世界的な糖尿病負荷の増大（特に1型と2型）は、速効型インスリン市場の主な促進要因です。International Diabetes Federationによると、2023年に5億3,000万人を超える成人が糖尿病を患っており、この数は着実に増加すると予測されています。このような糖尿病患者の増加は、食後の血糖を管理する効果的な速効型インスリン治療に対する需要の増加を直接の要因としています。より多くの患者が正確なインスリン投与を必要としているため、医療従事者は個別化された治療計画の一環として速効型インスリンを処方しています。政府や医療システムも糖尿病に対する認識や治療施設への投資を増やしており、市場の成長をさらに後押ししています。近年の予測では、世界中で5億3,700万人を超える成人が糖尿病を患っており、この数は2045年までに7億人に達すると推定されています。

インスリンデリバリーデバイスの進歩

インスリンペン、ポンプ、持続グルコースモニタリングシステムにおける技術の進歩は、速効型インスリンの利便性と有効性を大きく向上させました。現在のデリバリーデバイスは、患者に正確で簡単な投与を提供し、低血糖のリスクを低下させ、血糖のコントロールを最大化します。このような開発により、若年層や先進技術を利用した患者への速効型インスリン製剤の普及が進み、治療に対するアドヒアランスも向上しています。糖尿病管理アプリやスマートインスリンペンとの互換性も、これらのインスリン製剤の人気を高めています。より多くの医療機器企業と製薬企業が協力することで、これらの技術は治療を簡素化し、投与ミスを減らし、患者の生活の質を向上させ、市場の成長を支えています。2024年8月、AbbottとMedtronicは、AbbottのFreeStyle Libre技術に基づく統合型持続グルコースモニタリング（CGM）システムの開発で提携しました。このシステムは、Medtronicの自動インスリンデリバリーシステムとスマートインスリンペンシステムと組み合わされ、インスリン投与量を自動的に調整します。CGMセンサーはAbbottが設計し、Medtronicが販売します。

個別化された強化インスリン療法へのシフト

糖尿病治療における精密医療へのニーズの高まりにより、個別化された治療レジメンにおける速効型インスリンの重要性が高まっています。医師は現在、特に1型糖尿病患者やインスリンを使用している2型糖尿病患者を対象に、生理的インスリン分泌を厳密に反映した強化インスリン療法に関心を寄せています。速効型インスリンは、食事摂取後の血糖上昇を調節する、この戦略の重大な構成要素です。加えて、長期合併症のリスク軽減など、血糖コントロールの厳格化による患者の利益に対する認識も高まっています。患者中心の治療アプローチや、インスリン投与を指示するためのCGMデータの利用の増加により、速効型インスリンの需要が世界的に高まっています。2024年11月、InsuJet Needle-free Deviceは、革新的なジェット噴射技術を活用し、注射針を使用せずに正確なインスリン投与を行います。また、針注射に関する不快感や不安を軽減します。

速効型インスリン市場の障害

速効型インスリンの高いコスト

速効型インスリンの市場における大きな障害の1つは、特に医療が普及していない国ではコストがかかりすぎることです。インスリンリスプロとインスリンアスパルトは通常、ヒトインスリンより高い価格設定であるため、中低所得国の患者には利用できません。米国のような先進国市場でさえ、インスリンの入手性は依然として大きな問題であり、社会的圧力や政策行動の引き金となっています。価格の問題を解決するためにバイオシミラーが徐々に市場に出てきてはいますが、規制上の障害やブランド力が依然として抑制要因となっています。法外な価格は通常、高金利のインスリン配給、コンプライアンスの低下、望ましくない健康被害をもたらし、十分なサービスを受けていない地域における市場の将来性を汚します。

当レポートでは、世界の速効型インスリン市場について調査し、成長促進要因と課題、各セグメントの分析、主要企業の分析などを提供しています。

目次

第1章 イントロダクション

第2章 調査と調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 成長促進要因
• 課題
• 機会

第5章 世界の速効型インスリン市場

第6章 市場シェア分析

• 製品別
• 適応症別
• 流通チャネル別
• 国別

第7章 製品

• リスプロインスリン
• アスパルトインスリン
• グルリジンインスリン

第8章 適応症

• 1型糖尿病
• 2型糖尿病

第9章 流通チャネル

• 病院薬局
• ドラッグストア、薬局
• オンラインストア

第10章 国

• 北米
  • 米国
  • カナダ
• 欧州
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • ベルギー
  • オランダ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • タイ
  • マレーシア
  • インドネシア
  • ニュージーランド
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • トルコ
  • アラブ首長国連邦

第11章 ポーターのファイブフォース分析

第12章 SWOT分析

第13章 主要企業の分析

• Adocia
• Biocon Limited
• Eli Lilly and Company
• Gan & Lee Pharmaceuticals Co. Ltd.
• Geropharm
• MannKind Corporation
• Merck & Co. Inc.
• Novo Nordisk A/S
• Sanofi S.A.
• Wockhardt Ltd.

Rapid Acting Insulin Market Trends & Summary

The Rapid Acting Insulin Market valued at USD 7.71 billion in 2024 is anticipated to grow strongly to USD 11.77 billion by 2033. This growth represents a strong compound annual growth rate (CAGR) of 4.81% from 2025 to 2033."

The report Rapid Acting Insulin Market Forecast covers by Product (Lispro Insulin, Aspart Insulin, Glulisine Insulin), Indication (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), Country and Company Analysis 2025-2033.

The growth is supported by growing diabetes prevalence, the need for proper glycemic control, and improved insulin delivery technologies.

Rapid Acting Insulin Market Outlooks

Rapid acting insulin, or fast-acting insulin, starts to act between 10 to 30 minutes after injection, peaks within 1 to 3 hours, and lasts for as long as 5 hours. It is mostly utilized to control postprandial blood glucose surges in people with diabetes, primarily Type 1 and complicated Type 2 diabetes. Examples include insulin lispro, insulin aspart, and insulin glulisine.

These insulins are commonly used in combination with long-acting insulins in a basal-bolus regimen to more closely approximate the body's own insulin secretion. Their rapid onset makes them particularly suitable for flexible meal scheduling and improved postprandial glucose control. Globally, rapid-acting insulin is increasingly popular because of the growing number of diabetes cases, rising use of insulin pens and pumps, and increased awareness of early and effective diabetes care. Advancements in biosimilars and affordability programs are also improving worldwide access.

Growth Drivers for the Rapid Acting Insulin Market

Increasing Global Prevalence of Diabetes

The rising global diabetes burden, particularly Type 1 and Type 2, is a key driver for the rapid acting insulin market. As per the International Diabetes Federation, more than 530 million adults lived with diabetes in 2023, and the number is expected to increase consistently. This increase in diabetic patient populations is directly attributed to increasing demand for effective, fast-acting insulin treatments to manage postprandial blood glucose. As more patients need accurate insulin dosing, healthcare professionals are prescribing rapid acting insulin as part of personalized treatment plans. Governments and healthcare systems are also investing more in diabetes awareness and treatment facilities, further propelling market growth. As of recent projections, more than 537 million adults have diabetes worldwide, and this number is estimated to reach 700 million by 2045.

Advances in Insulin Delivery Devices

Technological advancements in insulin pens, pumps, and continuous glucose monitoring systems have greatly improved the convenience and effectiveness of rapid acting insulin. Current delivery devices offer patients precise, easy dosing, lowering the risk of hypoglycemia and maximizing glycemic control. These developments have aided increased uptake of rapid acting insulins by younger and more technologically advanced patients, along with better adherence to treatment. Compatibility with diabetes management apps and smart insulin pens also enhances the popularity of these insulins. With more device and pharmaceutical companies coming together, these technologies are simplifying therapy, decreasing administration errors, and improving the quality of life for patients, thereby supporting market growth. Aug 2024, Abbott and Medtronic have partnered to create an integrated continuous glucose monitoring (CGM) system based on Abbott's FreeStyle Libre technology. The system will be combined with Medtronic's automated insulin delivery and smart insulin pen systems to automatically adjust insulin doses. Abbott will design the CGM sensor and Medtronic will sell it.

Shift Toward Personalized and Intensive Insulin Therapy

The growing need for precision medicine in the management of diabetes has raised the level of importance for rapid acting insulin in individualized treatment regimens. Physicians are now concerned with intensive insulin therapy that reflects physiological insulin release closely, specifically for Type 1 diabetics and Type 2 diabetic patients who use insulin. Rapid acting insulin is a pivotal component of the strategy, regulating blood sugar excursions following food intake. In addition, awareness of patient benefits for tighter glycemic control, such as reduced risks of long-term complications, is growing. Coupled with patient-focused treatment approaches and increased application of CGM data to direct insulin dosing, demand for rapid acting insulin is being driven globally. Nov 2024, The InsuJet Needle-free Device harnesses innovative jet injection technology to administer accurate insulin doses without the use of needles. It reduces discomfort and anxiety concerning needle injections.

Drawbacks of the Rapid Acting Insulin Market

High Cost of Rapid Acting Insulin

One of the major drawbacks in the market of rapid acting insulin is that it is too costly, especially in nations lacking widespread healthcare coverage. Insulin lispro and insulin aspart are usually priced above human insulin, making them unavailable to low- and middle-income countries' patients. Even in developed markets such as the U.S., the affordability of insulin remains a significant issue that triggers public pressure as well as policy action. Although biosimilars are gradually coming into the market to fix the problem of price, regulatory obstacles and brand strength continue to be limiting factors. Exorbitant prices usually result in high rates of insulin rationing, lowered compliance, and undesirable health consequences, defiling market potential in underserved areas.

Regulated and Cold Chain Requirements

Manufacture, approval, and distribution of rapid acting insulin demand compliance with strict regulatory controls and temperature-controlled supply. Sustaining the cold chain during the supply chain is essential to ensuring insulin effectiveness and potency. This creates logistics issues, especially in developing countries with poor infrastructure. The process of regulatory approval for biosimilars is complicated and takes time, delaying entry into market and competition. Companies have to spend a lot on R&D and clinical trials in order to satisfy safety and efficacy requirements. These supply and regulatory restrictions can reduce product availability, influence pricing strategies, and impede the timely launch of new or enhanced formulations in international markets.

Lispro Rapid Acting Insulin Market

Insulin lispro, a top rapid acting insulin analog, is commonly used for its rapid onset and consistent post-meal glucose control. It generally starts to work within 15 minutes and is favored by both Type 1 and insulin-dependent Type 2 diabetics. Lispro is commonly prescribed in basal-bolus therapy regimens and is pump-compatible. Its availability in biosimilar form has also helped see more adoption in cost-conscious markets. Global pharmaceutical giants are making improvements in lispro formulations for improved stability and convenience of use. Continuing research and growing demand for rapid-acting alternatives in both hospital and outpatient environments continue to drive market growth.

Aspart Rapid Acting Insulin Market

Insulin aspart is a widely used rapid acting insulin analog characterized by its fast absorption and onset of action. Most commonly used in combination therapy with long-acting insulins, aspart has a vital role in controlling postprandial glucose levels. Both the original and biosimilar versions of aspart are widely available, rendering it possible to be implemented across different healthcare systems. The effectiveness, safety profile, and ease of use through insulin pens and pumps all contribute to aspart being favored by endocrinologists and diabetes health care professionals. While global diabetes incidence increases, demand for aspart grows, especially in markets where healthcare access and reimbursement of analog insulins are enhancing, driving consistent market growth.

Type 2 Diabetes Rapid Acting Insulin Market

Increase in prevalence of insulin-dependent Type 2 diabetes is greatly driving demand for rapid acting insulin. As the disease progresses in severity, most patients need post-meal insulin to get good glycemic control. Rapid acting insulin assists in controlling glucose peaks and lowering HbA1c levels in these patients, frequently as part of a multiple daily injection (MDI) regimen. With the increase in obesity rates and lack of physical activity, particularly in middle-income nations, the population of Type 2 patients who are moving towards insulin therapy is on the rise. Patient education regarding the advantages of analog insulins and more expansive reimbursement practices are also accelerating the uptake of rapid acting insulin in this group.

Rapid Acting Insulin Hospital Pharmacies Market

Hospital pharmacies have an important function to play in distributing rapid acting insulin, especially in newly diagnosed cases of diabetes or patients on inpatient status. These pharmacies guarantee stock availability of crucial insulin products, such as lispro and aspart, for quick glycemic control. Within hospitals, rapid-acting insulin is typically used in surgical recovery room, emergency room, or intensive care settings in which tight control of blood sugars is required. Additionally, caregivers depend on the hospital pharmacy to have immediate availability of specialty insulin pens and vials. With hospitals increasingly dealing with diabetes as a comorbidity in the management of various conditions, the channel will likely continue to dominate its robust share in the upcoming years.

Rapid Acting Insulin Online Retailers Market

Online pharmacies and online retail websites are becoming increasingly popular for the delivery of insulin, especially among urban and tech-literate populations. These websites are convenient, priced competitively, and easily provide branded and biosimilar rapid acting insulin products. Doorstep delivery, refill reminders, and teleconsultations are a boon to patients. As the COVID-19 pandemic unfolded, online purchases of insulin gained traction, underscoring its increasing significance. With growing digital health infrastructure and improved cold chain logistics, online sales channels are likely to keep on increasing. Governments and private sector players are also investing in secure, regulated e-pharmacy platforms to provide safe distribution, further solidifying the channel's significance in the insulin ecosystem.

United States Rapid Acting Insulin Market

The U.S. is among the most significant markets for rapid acting insulin with a high prevalence of diabetes, well-developed healthcare infrastructure, and early uptake of insulin delivery technology. Gaining access with increasing availability of biosimilar insulins and price reforms is becoming better. The major players are also working on bringing ultra-rapid formulations to the market to address demand from patients for improved control of postprandial levels and convenience. The FDA has approved Merilog (insulin-aspart-szjj) as a biosimilar to NovoLog (insulin aspart), and it is the first rapid-acting insulin biosimilar in the US. Effective February 14, 2025, this approval is intended to enhance patient access to rapid-acting insulin therapy and is available in both prefilled pens and multiple-dose vials.

France Rapid Acting Insulin Market

France boasts a robust healthcare system with clearly defined reimbursement policies that facilitate access to rapid acting insulin. The market is aided by early diagnosis rates, extensive diabetes education, and uptake of insulin delivery technologies such as pumps and pens. Government support for biosimilars is enhancing affordability. Moreover, France's emphasis on innovation and clinical research guarantees a constant flow of new treatments, promoting long-term market growth.

India Rapid Acting Insulin Market

India's rapid acting insulin market is growing driven by increasing prevalence of diabetes and growing awareness regarding contemporary insulin therapy. Urban communities are more prone to opt for rapid-acting insulin, aided by enhanced access through private hospitals and web platforms. Although affordability issues persist, the emergence of biosimilars and government schemes are improving availability in urban as well as semi-urban regions. Feb 2025, Cipla has obtained regulatory clearance to launch Afrezza, the world's first ultra-rapid-acting inhaled insulin, in India, a groundbreaking development in the management of diabetes.

Saudi Arabia Rapid Acting Insulin Market

The rapid acting insulin market of Saudi Arabia is increasing progressively with growth in diabetes treatment rates and increased government investment in healthcare facilities. Public and private initiatives are directed towards increasing access to advanced insulin therapies, such as analogs like lispro and aspart. Penetration of insulin pens and digital monitoring devices is increasing treatment adherence on a large scale. Educational campaigns and subsidized pricing programs are also enhancing insulin access throughout the regions. September 2024, Biocon has collaborated with Tabuk Pharmaceuticals for the commercialization of GLP-1 products for treating diabetes and weight control in the Middle East.

Rapid Acting Insulin Market Segments

Product

1. Lispro Insulin

2. Aspart Insulin

3. Glulisine Insulin

Indication

1. Type 1 Diabetes

2. Type 2 Diabetes

Distribution Channel

1. Hospital Pharmacies

2. Drug Stores and Retail Pharmacies

3. Online Stores

Country

North America

1. United States

2. Canada

Europe

1. France

2. Germany

3. Italy

4. Spain

5. United Kingdom

6. Belgium

7. Netherlands

8. Turkey

Asia Pacific

1. China

2. Japan

3. India

4. Australia

5. South Korea

6. Thailand

7. Malaysia

8. Indonesia

9. New Zealand

Latin America

1. Brazil

2. Mexico

3. Argentina

Middle East & Africa

1. South Africa

2. Saudi Arabia

3. UAE

All the key players have been covered from 4 Viewpoints:

• Overview
• Key Persons
• Recent Development
• Revenue

Company Analysis

1. Alcon Inc.

2. Bausch Health Companies Inc.

3. Carl Zeiss Meditec AG

4. EssilorLuxottica SA

5. HAAG-Streit Group

6. Hoya Corporation

7. Johnson and Johnson

8. Nidek Co. Ltd

9. Topcon Corporation

10. Ziemer Ophthalmic Systems AG

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges
• 4.3 Opportunities

5. Global Rapid Acting Insulin Market

6. Market Share Analysis

• 6.1 By Product
• 6.2 By Indication
• 6.3 By Distribution Channel
• 6.4 By Countries

7. Product

• 7.1 Lispro Insulin
• 7.2 Aspart Insulin
• 7.3 Glulisine Insulin

8. Indication

• 8.1 Type 1 Diabetes
• 8.2 Type 2 Diabetes

9. Distribution Channel

• 9.1 Hospital Pharmacies
• 9.2 Drug Stores and Retail Pharmacies
• 9.3 Online Stores

10. Countries

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
• 10.2 Europe
  • 10.2.1 France
  • 10.2.2 Germany
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Belgium
  • 10.2.7 Netherland
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 Australia
  • 10.3.5 South Korea
  • 10.3.6 Thailand
  • 10.3.7 Malaysia
  • 10.3.8 Indonesia
  • 10.3.9 New Zealand
• 10.4 Latin America
  • 10.4.1 Brazil
  • 10.4.2 Mexico
  • 10.4.3 Argentina
• 10.5 Middle East & Africa
  • 10.5.1 South Africa
  • 10.5.2 Saudi Arabia
  • 10.5.3 Turkey
  • 10.5.4 UAE

11. Porter's Five Forces Analysis

• 11.1 Bargaining Power of Buyers
• 11.2 Bargaining Power of Suppliers
• 11.3 Degree of Rivalry
• 11.4 Threat of New Entrants
• 11.5 Threat of Substitutes

12. SWOT Analysis

• 12.1 Strength
• 12.2 Weakness
• 12.3 Opportunity
• 12.4 Threat

13. Key Players Analysis

• 13.1 Adocia
  • 13.1.1 Overview
  • 13.1.2 Key Persons
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Development & Strategies
  • 13.1.5 Revenue Analysis
• 13.2 Biocon Limited
  • 13.2.1 Overview
  • 13.2.2 Key Persons
  • 13.2.3 Product Portfolio
  • 13.2.4 Recent Development & Strategies
  • 13.2.5 Revenue Analysis
• 13.3 Eli Lilly and Company
  • 13.3.1 Overview
  • 13.3.2 Key Persons
  • 13.3.3 Product Portfolio
  • 13.3.4 Recent Development & Strategies
  • 13.3.5 Revenue Analysis
• 13.4 Gan & Lee Pharmaceuticals Co. Ltd.
  • 13.4.1 Overview
  • 13.4.2 Key Persons
  • 13.4.3 Product Portfolio
  • 13.4.4 Recent Development & Strategies
  • 13.4.5 Revenue Analysis
• 13.5 Geropharm
  • 13.5.1 Overview
  • 13.5.2 Key Persons
  • 13.5.3 Product Portfolio
  • 13.5.4 Recent Development & Strategies
  • 13.5.5 Revenue Analysis
• 13.6 MannKind Corporation
  • 13.6.1 Overview
  • 13.6.2 Key Persons
  • 13.6.3 Product Portfolio
  • 13.6.4 Recent Development & Strategies
  • 13.6.5 Revenue Analysis
• 13.7 Merck & Co. Inc.
  • 13.7.1 Overview
  • 13.7.2 Key Persons
  • 13.7.3 Product Portfolio
  • 13.7.4 Recent Development & Strategies
  • 13.7.5 Revenue Analysis
• 13.8 Novo Nordisk A/S
  • 13.8.1 Overview
  • 13.8.2 Key Persons
  • 13.8.3 Product Portfolio
  • 13.8.4 Recent Development & Strategies
  • 13.8.5 Revenue Analysis
• 13.9 Sanofi S.A.
  • 13.9.1 Overview
  • 13.9.2 Key Persons
  • 13.9.3 Product Portfolio
  • 13.9.4 Recent Development & Strategies
  • 13.9.5 Revenue Analysis
• 13.10 Wockhardt Ltd.
  • 13.10.1 Overview
  • 13.10.2 Key Persons
  • 13.10.3 Product Portfolio
  • 13.10.4 Recent Development & Strategies
  • 13.10.5 Revenue Analysis